StephanieBoisclairMD

PubMed

• 27 citations
  Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
  Yazan Numan, Zaid Abdel Rahman, Justin Grenet, Stephanie Boisclair, Jan Philipp Bewersdorf
  American Journal of Hematology. 2022-03-01
• 1 citations
  Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria.
  Farhana Begum, Nida Khan, Stephanie Boisclair, Deepa A Malieckal, David Chitty
  American Journal of Therapeutics. 2023-05-01
• Use of Mogamulizumab for Cutaneous Adult T-cell Leukemia in a Patient Living With HIV.
  Stephanie Boisclair, Amanda Brahim, Jose Sandoval-Sus
  Cureus. 2022-11-01

Abstracts/Posters

• Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
  Stephanie Boisclair, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
  Stephanie Boisclair, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation
  Stephanie Boisclair, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019